Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized photodynamic therapy for basal cell carcinoma
2016-002508-16Phase 4Terminated
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jul 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methyl aminolevulinate in basal cell carcinoma (BCC), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Complete tumor clearance. Started Jul 2016; status: terminated.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2016-002508-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002508-16.